A day after Prime Minister Narendra Modi introduced that the Centre is taking again vaccine-buying from states, the finance ministry stated the programme will price round Rs 50,000 crore and the federal government has the cash.
“We don’t need to go for the supplementary grants immediately as there are enough funds. We may have to go for this in the second round, near the winter session of Parliament. At present we have the money,” Finance Ministry sources stated.
The sources additionally indicated that the federal government is not relying on overseas vaccines to fulfill its vaccine wants.
“Our programme of procurement is centred around Bharat Biotech, Serum Institute and the new Bio-E; we will be able to supply vaccines for the substantial population from these vaccines,” sources stated.
Talks with Pfizer and Moderna are reportedly caught on the indemnity demand by the vaccine makers.
Besides Bharat Biotech’s Covaxin and Serum Institute of India’s Covishield, Russia’s Sputnik V has been cleared to be used within the nation.
But Sputnik “will not be substantial” in quantity, stated officers, including, “We haven’t started procurement for this still.”
The authorities final week stated it has booked 30 crore doses of Hyderabad-based Biological-E’s Covid vaccine, which remains to be in scientific trials. The Health Ministry will make an advance fee of Rs 1,500 crore to the corporate for what would be the second made-in-India vaccine after Covaxin.
On Dearness Allowance to central authorities staff, sources stated the choice is to present it from July 1 prospectively and never retrospectively with arrears.
“We can’t have both free vaccine and increase in Dearness Allowance with retrospective effect. We have to prioritise and decide what’s more important,” officers stated.